Additional Information

Description

Ibandronic acid belongs to calcium metabolism modifiers bisphosphonate derivatives and is intended for intravenous administration. The syringe readily delivers 3.375mg of the active constituent through 3 ml of solvent, administered as a 15 - 30 seconds IV bolus or infused over 1 hour for metastatic bone disease.

Ibandronic acid is prescribed to lessen bone damage during metastases in breast cancer and to reduce elevated serum calcium levels which result in tumors (hypercalcemia). Post-menopausal osteoporosis is also one of the indications of Ibandronic acid, where the function is to reduce the risk of fractures. It increases bone mineral density by inhibiting osteoclast-mediated bone resorption. The mechanism of action of Ibondronic acid in post-menopausal women is to lessen the elevated bone turnover rate which results in the retention of bone mass.

Calcium-containing products should be administered at least 60 minutes after the dosage. It is contraindicated in pregnancy and lactation. Renal function, serum calcium, phosphate, and magnesium should be monitored during the treatment.